How soon can I see the effects of Sotorasib?

Sotorasib is an inhibitor that targets the KRAS G12C mutation and is mainly used to treat patients with non-small cell lung cancer (NSCLC) with mutations in this gene. As the first approved targeted drug targeting KRAS mutations, sotoraxib has demonstrated a relatively rapid anti-tumor response in clinical trials. Many patients see some improvement in their condition soon after taking the drug.

Judging from the existing clinical research data, some patients can initially observe changes in their condition within 2 to 4 weeks after receiving sotoraxib treatment, such as symptom reduction, improvement in physical strength, or relief of pulmonary symptoms such as cough and dyspnea. At the same time, imaging examinations may show reduction in tumor size or stabilization of lesions at the first evaluation (usually scheduled 4 to 6 weeks after taking the drug).

However, some patients have a slower onset of effect, and may not show obvious effects until 6 to 8 weeks or even longer after treatment. This is often related to tumor load, physical condition and genetic characteristics. Therefore, although sotoracib may be effective in the short term, you still need to wait patiently during the treatment process and conduct regular imaging reviews to accurately judge the efficacy.

In short, the onset of effect of sotoraxib varies from person to person. Generally, initial reactions may occur 1 to 2 cycles (about 1 months) after taking the drug. In order to give full play to the efficacy of the drug, patients should insist on taking the medication on time, review it regularly, and follow the doctor's instructions for individualized treatment adjustments to ensure timely intervention when poor efficacy or side effects are found.

Reference materials:https://www.lumakras.com/